オメガ3脂肪酸エチルエステル顆粒カプセル製剤の特定医薬品使用調査：OCEAN3

基本情報

NCT ID: NCT02285166
ステータス: 完了
試験のフェーズ: -
試験タイプ: 観察
目標被験者数: 15,330
治験依頼者名: Takeda

概要

The purpose of this survey is to determine the incidence rate of cardiovascular (CV) events associated with long-term treatment with and without omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) in high-risk hyperlipidemic patients treated by statin in daily medical practice.

対象疾患

Hyperlipidemia

介入

Omega-3 fatty acid ethyl esters(DRUG)

Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).(DRUG)

依頼者（Sponsor）

武田薬品工業株式会社(INDUSTRY)